Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Cash from Investing Activities of $172.6 million for Q1 2026, up 1182.29% year-over-year from $13.5 million in Q1 2025, and up 130.52% quarter-over-quarter from $74.9 million in Q4 2025.
Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Revolution Medicines' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $172.6 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 1182.29% year-over-year to $172.6 million; the TTM figure through Mar 2026 stood at $306.6 million (up 195.11% YoY), while the FY2025 annual figure was $118.1 million, up 121.29% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $172.6 million, up from $74.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $172.6 million in Q1 2026, with the low at -$392.9 million in Q4 2024.
- The 5-year median for Cash from Investing Activities is $4.0 million (2023), against an average of -$37.1 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 1806.67% in 2022, then tumbled 6305.36% in 2024.
- Revolution Medicines' Cash from Investing Activities stood at -$7.1 million in 2022, then plunged by 5254.76% to -$380.4 million in 2023, then slipped by 3.29% to -$392.9 million in 2024, then jumped by 119.06% to $74.9 million in 2025, then soared by 130.52% to $172.6 million in 2026.
- Business Quant data shows RVMD's Cash from Investing Activities at $172.6 million in Q1 2026, $74.9 million in Q4 2025, and $24.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 281.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.66 Bn |
| Jun 30, 2026 | -1.66 Bn |
| Mar 31, 2026 | 172.62 Mn |
| Mar 31, 2026 | 172.62 Mn |
| Dec 31, 2025 | 74.88 Mn |
| Dec 31, 2025 | 74.88 Mn |
| Sep 30, 2025 | 24.85 Mn |
| Sep 30, 2025 | 24.85 Mn |
| Jun 30, 2025 | 34.28 Mn |
| Jun 30, 2025 | 34.28 Mn |
| Mar 31, 2025 | -15.95 Mn |
| Mar 31, 2025 | -15.95 Mn |
| Dec 31, 2024 | -392.90 Mn |
| Dec 31, 2024 | -392.90 Mn |
| Sep 30, 2024 | -21.47 Mn |
| Sep 30, 2024 | -21.47 Mn |
| Jun 30, 2024 | 107.94 Mn |
| Jun 30, 2024 | 107.94 Mn |
| Mar 31, 2024 | -247.97 Mn |
| Mar 31, 2024 | -247.97 Mn |